ABBV edges out PFE as Skyrizi and Rinvoq fuel strong growth, offsetting Humira losses and positioning the drugmaker for sustained expansion.

The company has increased its payouts over the past five years despite significant challenges.

On the second trading day of the week, Pfizer (NYSE: PFE) was a laggard on the stock exchange. An analyst reiterated his ...

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

The healthcare stock looks ridiculously undervalued.

If you are wondering whether Pfizer at around US$27.47 is a bargain or a value trap, the key is understanding what the current price actually implies about the company. The stock is up 9.1% year to ...

Pfizer Inc. (NYSE:PFE) plays a significant role in global healthcare by supplying medicines and vaccines to healthcare ...

Pfizer Inc PFE shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot ...

Bristol Myers Squibb BMY has delivered a strong performance year to date with its shares gaining 10.2% compared with the ...

Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter ...

Find the latest better.com news from Fast company. See related business and technology articles, photos, slideshows and ...